Enalapril-d5 (maleate) – 500 µg

Brand:
Cayman
CAS:
349554-02-5
Storage:
-20
UN-No:
Non-Hazardous - /

Enalapril-d5 is intended for use as an internal standard for the quantification of enalapril (Item No. 16041) by GC- or LC-MS. Enalapril is an inhibitor of angiotensin-converting enzyme (ACE; IC50 = 1.2 nM in porcine plasma).{43103} In vivo, enalapril (0.05-1 mg/kg, p.o.) inhibits pressor responses induced by angiotensin I (Item No. 24737) in rats and dogs in a dose-dependent manner. Enalapril reduces heart rate, systolic and diastolic blood pressures, and heart weight/body weight ratio in salt-sensitive and -resistant Dahl rats fed a high-salt or low-salt diet.{43104} Formulations containing enalapril have been used for the treatment of hypertension, congestive heart failure, myocardial infarction, and diabetic nephropathies.{25199}  

 

Available on backorder

SKU: 25318 - 500 µg Category:

Description

An internal standard for the quantification of enalapril by GC- or LC-MS


Formal name: N-[1-(ethoxycarbonyl)-3-(phenyl-d5)propyl]-L-alanyl-L-proline, 2Z-butenedioate

Synonyms: 

Molecular weight: 497.6

CAS: 349554-02-5

Purity: ≥99% deuterated forms (d1-d5)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Small Molecule Inhibitors|Angiotensin-converting Enzyme||Product Type|Biochemicals|Small Molecule Inhibitors|MMPs||Research Area|Cardiovascular System|Cardiovascular Diseases|Heart Failure||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Cardiovascular Diseases|Myocardial Infarction||Research Area|Cardiovascular System|Kidney & Renal Disease|Diabetic Nephropathy||Research Area|Cardiovascular System|Vasculature|Vasodilation